NUVBNuvation Bio Inc.Signing up patients
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Non Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 194 (planned)
- Started
- Nov 27, 2024
- Main results expected
- Jan 2029
- Fully finished
- Sep 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PFS (Assessed by BIRC)
Measured over: About 49 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06564324 · record last updated 2026-04-13 · checked 2026-11-09 15:47 UTC